Related Experiment Videos
Phase II study of 5-azacytidine in solid tumors
Cancer Treatment Reports
|January 1, 1977
Summary
This Phase II study of 5-azacytidine in solid tumors showed limited efficacy, with few partial regressions and significant myelosuppressive and gastrointestinal toxicities. The drug demonstrated poor response quality and duration, associated with substantial treatment-related deaths.
Area of Science:
- Oncology
- Pharmacology
Background:
- 5-azacytidine is an epigenetic modifier investigated for cancer treatment.
- Solid tumors represent a diverse group of malignancies with varying treatment responses.
Purpose of the Study:
- To evaluate the efficacy and toxicity of 5-azacytidine in patients with advanced solid tumors.
- To determine optimal dosing based on observed toxicities.
Main Methods:
- A Phase II clinical trial (SWOG-7208) enrolled patients with solid tumors.
- Dosing of 5-azacytidine was escalated and de-escalated (225, 175, 150 mg/m2) due to toxicity.
- Patient responses and adverse events were meticulously recorded.
Main Results:
- Only 2.6% of eligible patients achieved partial regression, lasting 28-77 days.
- 16 patients (8.4%) experienced stable disease for 39-255 days.
- Major toxicities included myelosuppression and gastrointestinal issues, leading to 13 deaths (11 sepsis, 2 cerebral hemorrhage).
Conclusions:
- 5-azacytidine demonstrated minimal favorable responses in solid tumors.
- Observed responses were generally of poor quality and short duration.
- Significant drug-related toxicity, including fatal events, limits its therapeutic utility in this setting.